Conflicts of interests in academia are indeed a web of intrigue, as eminently portrayed by Smith. 1 There are certain conflicts of interest though, which are married to research and are bigger than money, and yet are never disclosed. Glory of publishing and career progression are two such factors. The purpose of research is to answer a question; but are all researchers honest to this purpose? What happens when research becomes a means for achieving personal gain? Consider the case of young impassioned clinicians, who delve into research. Their goal is to append as much weight to their curriculum vitae as possible by 'getting publications'. How committed are they towards forwarding science? Senior academics are no less prone to such conflicts of interest with elements such as the research assessment exercise lurking in the background. Hunger for authorship, recognition and position can be as corruptive as the apple of Adam. They will, unfortunately, probably remain the bugbears of research, forever.
Competing interests None declared. A recent systematic review suggested that the incidence of rhabdomyolysis was 4 times higher for monotherapy with statins like lovastatin, simvastatin, or atorvastatin which are oxidized by CYP3A4 (mean-rate=0.73; 95% CI: 0.64-0.82/million prescriptions), compared to monotherapy with pravastatin or fluvastatin that are not oxidized by CYP3A4 (mean-rate=0.15; 95% CI: 0.09-0.24/million prescriptions, P50.001). 2 In persons taking simvastatin, lovastatin, or atorvastatin, 60% of cases involved drugs known to inhibit CYP3A4, and 19% involved fibrates, principally gemfibrozil; a substrate of CYP3A4. 2 Examples of further commonly used drugs that inhibit CYP3A4 include diltiazem, erythromycin, azole antifungals, ritonavir, cyclosporine and also grapefruit juice. 2 Of note, pioglitazone, clopidogrel and colchicine are also related to CYP3A4 in their metabolism. Patients who received a lipid-lowering medication with a concomitant CYP3A4 inhibitor have been demonstrated to have a 6-fold increased rate of muscle disorders, including non-traumatic rhabdomyolysis.
The risk of arrhythmias with diabetes mellitus is high, 5 and amid the increasing benefits of statins in diabetes mellitus, as well as decreasing threshold to use statins, clinicians should be vigilant about muscle-related complaints, especially in elderly patients on multiple medications. Avoiding or suspending the concomitant use of drugs metabolised through the CYP3A4 system or alternatively, if drug therapy with a potent CYP3A4 inhibitor is inevitable, choosing a statin without relevant CYP3A4 metabolism should be considered. Indeed, the potential for these complications are less commonly perceived in routine daily clinical practice.
